Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.